Phosphoinositide protein kinase PDPK1 is a crucial cell signaling mediator in multiple myeloma

Cancer Research

Volumn 74, Issue 24, 2014, Pages 7418-7429

  Chinen, Yoshiaki ^a   Kuroda, Junya ^a   Shimura, Yuji ^a   Nagoshi, Hisao ^a   Kiyota, Miki ^a   Yamamoto Sugitani, Mio ^a   Mizutani, Shinsuke ^a   Sakamoto, Natsumi ^a   Ri, Masaki ^b   Kawata, Eri ^c   Kobayashi, Tsutomu ^a   Matsumoto, Yosuke ^a   Horiike, Shigeo ^a   Iida, Shinsuke ^b   Taniwaki, Masafumi ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c KYOTO SECOND RED CROSS HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; BORTEZOMIB; CYCLIN D; DEXAMETHASONE; FIBROBLAST GROWTH FACTOR RECEPTOR 3; INTERFERON REGULATORY FACTOR 4; LENALIDOMIDE; MELPHALAN; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN BAD; PROTEIN KINASE; PROTEIN KINASE B; RSK2 PROTEIN; UNCLASSIFIED DRUG; 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE; PDPK1 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER INHIBITION; CANCER PROGNOSIS; CANCER STAGING; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MEGADOSE; FGFR3 GENE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; ONCOGENE RAS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; ANTAGONISTS AND INHIBITORS; CARCINOGENESIS; DISEASE FREE SURVIVAL; FEMALE; GENETICS; MALE; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; VERY ELDERLY;

3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASES; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOGENESIS; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MULTIPLE MYELOMA; SIGNAL TRANSDUCTION;

EID: 84918511308     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-1420     Document Type: Article

References (50)

1. Kuehl WM, Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest 2012;122:3456-63.
2. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer 2012;12:335-48.
3. Harousseau JL. Ten years of improvement in the management of multiple myeloma: 2000-2010. Clin Lymphoma Myeloma Leuk 2010;10:424-42.
4. Gay F, Larocca A, Wijermans P, Cavallo F, Rossi D, Schaafsma R, et al. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood 2011;117:3025-31.
5. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-20.
6. Kuroda J, Shimura Y, Ohta K, Tanaka H, Shibayama H, Kosugi S, et al. Limited value of the International Staging System for predicting longterm outcome of transplant-ineligible, newly diagnosed, symptomatic multiple myeloma in the era of novel agents. Int J Hematol 2014;99:441-9.
7. Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007;110:3281-90.
8. Lacy MQ, Allred JB, Gertz MA, Hayman SR, Short KD, Buadi F, et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood 2011;118:2970-5.
9. Kuroda J, Nagoshi H, Shimura Y, Taniwaki M. Elotuzumab and daratumumab: emerging new monoclonal antibodies for multiple myeloma. Expert Rev Anticancer Ther 2013;13:1081-8.
10. Steinbrunn T, Stühmer T, Gattenlöhner S, Rosenwald A, Mottok A, Unzicker C, et al. Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival. Blood 2011;117:1998-2004.
11. Chng WJ, Gonzalez-Paz N, Price-Troska T, Jacobus S, Rajkumar SV, Oken MM,et al. Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia 2008;22:2280-4.
12. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011;471:467-72.
13. Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM, et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009;137:873-86.
14. Zöllinger A, Stühmer T, Chatterjee M, Gattenlöhner S, Haralambieva E, Müller-Hermelink HK, et al. Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Aktdependent and Akt-independent multiple myeloma. Blood 2008;112:3403-11.
15. Liu P, Leong T, Quam L, Billadeau D, Kay NE, Greipp P, et al. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood 1996;88:2699-706.
16. Ramakrishnan V, Kimlinger T, Haug J, Painuly U, Wellik L, Halling T, et al. Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway. PLoS ONE2012;7:e50005.
17. Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, et al. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 2002; 21:5673-83.
18. Ocio EM, Mateos MV, Maiso P, Pandiella A, San-Miguel JF. New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncol 2008;9:1157-65.
19. Richardson PG, Wolf J, Jakubowiak A, Zonder J, Lonial S, Irwin D, et al. Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. J Clin Oncol 2011;29:4243-9.
20. Richardson PG, Mitsiades CS, Laubach JP, Lonial S, Chanan-Khan AA, Anderson KC. Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Br J Haematol 2011;152:367-79.
21. Ghobrial IM, Weller E, Vij R, Munshi NC, Banwait R, Bagshaw M, et al. Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. Lancet Oncol 2011;12:263-72.
22. Will M, Qin AC, Toy W, Yao Z, Rodrik-Outmezguine V, Schneider C, et al. Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling. Cancer Discov 2014;4:334-47.
23. Zimmermann S, Moelling K. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 1999;286:1741-4.
24. Steinbrunn T, Stühmer T, Sayehli C, Chatterjee M, Einsele H, Bargou RC. Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma. Br J Haematol 2012;159:430-40.
25. Shimura Y, Kuroda J, Ri M, Nagoshi H, Yamamoto-Sugitani M, Kobayashi T, et al. RSK2(Ser227) at N-terminal kinase domain is a potential therapeutic target for multiple myeloma. Mol Cancer Ther 2012;11:2600-9.
26. Anjum R, Blenis J. The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol 2008;9:747-58.
27. Peifer C, Alessi DR. Small-molecule inhibitors of PDK1. Chem Med Chem 2008;3:1810-38.
28. Roecklein BA, Torok-Storb B. Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus E6/E7 genes. Blood 1995;85:997-1005.
29. Ri M, Iida S, Nakashima T, Miyazaki H, Mori F, Ito A, et al. Bortezomibresistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia 2010;24:1506-12.
30. Kiyota M, Kobayashi T, Fuchida S, Yamamoto-Sugitani M, Ohshiro M, Shimura Y, et al. Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma. Int J Hematol 2012; 95:516-26.
31. Feldman RI, Wu JM, Polokoff MA, Kochanny MJ, Dinter H, Zhu D, et al. Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem 2005;280:19867-74.
32. Zhang S, Suvannasankha A, Crean CD, White VL, Johnson A, Chen CS, et al. OSU-03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms. Clin Cancer Res 2007;13:4750-8.
33. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005;106:296-303.
34. Nakamura K, Sakaue H, Nishizawa A, Matsuki Y, Gomi H, Watanabe E, et al. PDK1 regulates cell proliferation and cell cycle progression through control of cyclin D1 and p27Kip1 expression. J Biol Chem 2008;283:17702-11.
35. Moreaux J, Cremer FW, Reme T, Raab M, Mahtouk K, Kaukel P, et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 2005;106:1021-30
36. Huo J, Xu S, Lin B, Chng WJ, Lam KP. Fas apoptosis inhibitory molecule is upregulated by IGF-1 signaling and modulates Akt activation and IRF4 expression in multiple myeloma. Leukemia 2013;27:1165-71.
37. Casamayor A, Morrice NA, Alessi DR. Phosphorylation of Ser-241 is essential for the activity of 3-phosphoinositide-dependent protein kinase-1: identi fication of five sites of phosphorylation in vivo. Biochem J 1999;342:287-92.
38. Venigalla RK, McGuire VA, Clarke R, Patterson-Kane JC, Najafov A, Toth R, et al. PDK1 regulates VDJ recombination, cell-cycle exit and survival during B-cell development. EMBO J 2013;32:1008-22.
39. Park SG, Long M, Kang JA, Kim WS, Lee CR, Im SH, et al. The kinase PDK1 is essential for B-cell receptor mediated survival signaling. PLoS ONE 2013;8:e55378.
40. Eser S, Reiff N, Messer M, Seidler B, Gottschalk K, Dobler M, et al. Selective requirement of PI3K/PDK1 signaling for Kras oncogenedriven pancreatic cell plasticity and cancer. Cancer Cell 2013;23:406-20.
41. Lu Z, Cox-Hipkin MA, Windsor WT, Boyapati A. 3-phosphoinositidedependent protein kinase-1 regulates proliferation and survival of cancer cells with an activated mitogen-activated protein kinase pathway. Mol Cancer Res 2010;8:421-32.
42. Zabkiewicz J, Pearn L, Hills RK, Morgan RG, Tonks A, Burnett AK, et al. The PDK1 master kinase is overexpressed in acute myeloid leukemia and promotes PKC-mediated survival of leukemic blasts. Haematologica 2014;99:858-64.
43. Tan J, Li Z, Lee PL, Guan P, Aau MY, Lee ST, et al. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy. Cancer Discov 2013;3:1156-71.
44. Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, Xiao W, et al. IRF4 addiction in multiple myeloma. Nature 2008;454:226-31.
45. Mora A, Davies AM, Bertrand L, Sharif I, Budas GR, Jovanović S, et al. Deficiency of PDK1 in cardiac muscle results in heart failure and increased sensitivity to hypoxia. EMBO J 2003;22:4666-76.
46. Ellwood-Yen K, Keilhack H, Kunii K, Dolinski B, Connor Y, Hu K, et al. PDK1 attenuation fails to prevent tumor formation in PTEN-deficient transgenic mouse models. Cancer Res 2011;71:3052-65.
47. Hotte SJ, Oza A, Winquist EW, Moore M, Chen EX, Brown S, et al. Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study. Ann Oncol 2006;17:334-40.
48. Lawlor MA, Mora A, Ashby PR, Williams MR, Murray-Tait V, Malone L, et al. Essential role of PDK1 in regulating cell size and development in mice. EMBO J 2002;21:3728-38.
49. Yan JW, Lin JS, He XX. The emerging role of miR-375 in cancer. Int J Cancer 2014;135:1011-8.
50. Gutiérrez NC, Sarasquete ME, Misiewicz-Krzeminska I, Delgado M, De Las Rivas J, Ticona FV, et al. Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia 2010;24:629-37.